MDS 2023 | Differences and similarities between MDS and AML & how this can inform treatment decisions
Eytan Stein, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, highlights some of the controversies in characterizing and distinguishing myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Dr Stein explains that whilst high-risk MDS and low-blast count AML are very similar, it is important to look for co-occurring molecular alterations in patients with HR-MDS compared to patients with AML when selecting a therapy. This interview took place at the 17th International Congress on Myelodysplastic Syndromes 2023 (MDS 2023) held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Astellas Pharmaceutical, Agios Pharmaceuticals, and Genentech: Consultancy, Membership on an entity’s Board of Directors or advisory committees; PTC Therapeutics and Syros: Membership on an entity’s Board of Directors or advisory committees; Syndax: Consultancy, Research Funding; Amgen, AbbVie, Seattle Genetics, and Biotheryx: Consultancy; Daiichi-Sankyo, Celgene Pharmaceuticals, and Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Auron Therapeutics: Current equity holder in private company; PinotBio, Bristol Myers Squibb, Jazz Pharmaceuticals, Foghorn Therapeutics, Blueprint Medicines, Gilead Sciences, Janssen Pharmaceuticals: Consultancy; Bayer: Research Funding.
